Publications by authors named "Erika Rijavec"

Claim this Profile
C
Cytomegalovirus gastritis as a rare adverse event during combined ipilimumab and nivolumab in a patient with melanoma.
Alice Indini, Rossana Gueli, Michele Cerati, Erika Rijavec, Marco Parravicini

Melanoma Res· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Extracellular vesicles miR-574-5p and miR-181a-5p as prognostic markers in NSCLC patients treated with nivolumab.
Carlo Genova, Silvia Marconi, Giovanna Chiorino, Francesca Guana, Paola Ostano, Erika Rijavec

Clin Exp Med· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Management of patients with extensive small-cell lung cancer in the immunotherapy era: An Italian consensus through a Delphi approach.
Giovanni Luca Ceresoli, Giulio Rossi, Francesco Agustoni, Lucia Bonomi, Paolo Borghetti, Erika Rijavec

Crit Rev Oncol Hematol· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety of extended interval dosing immune checkpoint inhibitors: a multicenter cohort study.
Luca Cantini, Francesco Paoloni, Federica Pecci, Francesco Spagnolo, Carlo Genova, Erika Rijavec

J Natl Cancer Inst· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic Role of Soluble and Extracellular Vesicle-Associated PD-L1, B7-H3 and B7-H4 in Non-Small Cell Lung Cancer Patients Treated with Immune Checkpoint Inhibitors.
Carlo Genova, Roberta Tasso, Alessandra Rosa, Giovanni Rossi, Daniele Reverberi, Erika Rijavec

Cells· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-line nivolumab plus ipilimumab for metastatic non-small cell lung cancer, including patients with ECOG performance status 2 and other special populations: CheckMate 817.
Neal E Ready, Clarisse Audigier-Valette, Jonathan W Goldman, Enriqueta Felip, Tudor-Eliade Ciuleanu, Erika Rijavec

J Immunother Cancer· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immune checkpoint inhibitor therapy for hepatocellular carcinoma.
Daryl Ramai, Alexandra Shapiro, Antonio Facciorusso, Claudia Bareggi, Donatella Gambini, Erika Rijavec

Ann Gastroenterol· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neoadjuvant Chemo-Immunotherapy for Locally Advanced Non-Small-Cell Lung Cancer: A Review of the Literature.
Sara Franzi, Giovanni Mattioni, Erika Rijavec, Giorgio Alberto Croci, Davide Tosi

J Clin Med· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical outcomes of NSCLC patients experiencing early immune-related adverse events to PD-1/PD-L1 checkpoint inhibitors leading to treatment discontinuation.
Marco Russano, Alessio Cortellini, Raffaele Giusti, Alessandro Russo, Federica Zoratto, Erika Rijavec

Cancer Immunol Immunother· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel approaches for the treatment of unresectable malignant pleural mesothelioma: A focus on immunotherapy and target therapy (Review).
Erika Rijavec, Federica Biello, Giulia Barletta, Chiara Dellepiane, Carlo Genova

Mol Clin Oncol· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Renal Function Outcomes in Metastatic Non-Small-Cell Lung Carcinoma Patients Treated with Chemotherapy or Immune Checkpoint Inhibitors: An Unexpected Scenario.
Francesco Trevisani, Federico Di Marco, Matteo Floris, Antonello Pani, Roberto Minnei, Erika Rijavec

Vaccines (Basel)· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Host immune-inflammatory markers to unravel the heterogeneous outcome and assessment of patients with PD-L1 ≥50% metastatic non-small cell lung cancer and poor performance status receiving first-line immunotherapy.
Giuseppe L Banna, Marcello Tiseo, Diego L Cortinovis, Francesco Facchinetti, Joachim G J V Aerts, Erika Rijavec

Thorac Cancer· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Serum levels of VCAM-1 are associated with survival in patients treated with nivolumab for NSCLC.
Federico Carbone, Stefano Ministrini, Aldo Bonaventura, Alessandra Vecchié, Silvia Minetti, Erika Rijavec

Eur J Clin Invest· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Current Insights on the Treatment of Anaplastic Lymphoma Kinase-Positive Metastatic Non-Small Cell Lung Cancer: Focus on Brigatinib.
Erika Rijavec, Federica Biello, Alice Indini, Francesco Grossi, Carlo Genova

Clin Pharmacol· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Total neoadjuvant therapy for initially inoperable pancreatic cancer: A systematic review of phase 2-3 studies.
Gianluca Tomasello, Michele Ghidini, Antonio Ghidini, Francesca Trevisan, Andrea Celotti, Erika Rijavec

Radiother Oncol· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Current state of the art and future perspectives with immunotherapy in the management of small cell lung cancer.
Erika Rijavec, Carlo Genova, Federica Biello, Giovanni Rossi, Alice Indini

Expert Rev Respir Med· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
COVID-19 vaccination mimicking lymph-node progression in a patient with melanoma: a case report.
Alice Indini, Stefano Costa, Anna Maria Ierardi, Erika Rijavec, Emanuela Passoni

Melanoma Res· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Metabolic disorders and the risk of cholangiocarcinoma.
Michele Ghidini, Daryl Ramai, Antonio Facciorusso, Jameel Singh, Waqqas Tai, Erika Rijavec

Expert Rev Gastroenterol Hepatol· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Role of the Immune Metabolic Prognostic Index in Patients with Non-Small Cell Lung Cancer (NSCLC) in Radiological Progression during Treatment with Nivolumab.
Matteo Bauckneht, Carlo Genova, Giovanni Rossi, Erika Rijavec, Maria Giovanna Dal Bello

Cancers (Basel)· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting KRAS in Solid Tumors: Current Challenges and Future Opportunities of Novel KRAS Inhibitors.
Alice Indini, Erika Rijavec, Michele Ghidini, Alessio Cortellini, Francesco Grossi

Pharmaceutics· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy.
Alessio Cortellini, Massimo Di Maio, Olga Nigro, Alessandro Leonetti, Diego L Cortinovis, Erika Rijavec

J Immunother Cancer· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Circulating Biomarkers of Response and Toxicity of Immunotherapy in Advanced Non-Small Cell Lung Cancer (NSCLC): A Comprehensive Review.
Alice Indini, Erika Rijavec, Francesco Grossi

Cancers (Basel)· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Trastuzumab Deruxtecan: Changing the Destiny of HER2 Expressing Solid Tumors.
Alice Indini, Erika Rijavec, Francesco Grossi

Int J Mol Sci· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of BMI on Survival Outcomes of Immunotherapy in Solid Tumors: A Systematic Review.
Alice Indini, Erika Rijavec, Michele Ghidini, Gianluca Tomasello, Monica Cattaneo

Int J Mol Sci· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Appropriateness of Invasive Ventilation in COVID-19 Positive Cancer Patients: Proposal of a New Prognostic Score.
Michele Ghidini, Alice Indini, Erika Rijavec, Claudia Bareggi, Monica Cattaneo

Viruses· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis